RecruitingPhase 2NCT05128825
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Intervention
- azenosertib(drug)
- Enrollment
- 310 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2022 – 2027
Study locations (30)
- Site 0170-USA Mitchell Cancer Institute, Mobile, Alabama, United States
- Site 0143 - HonorHealth, Phoenix, Arizona, United States
- Site 0102 - University of Arizona Cancer Center, Tucson, Arizona, United States
- Site 0258 - UC San Diego Moores Cancer Center, La Jolla, California, United States
- Site 0287 - Ridley Tree Cancer Center, Santa Barbara, California, United States
- Site 0135 - Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
- Site 0158 - Hartford HealthCare, Hartford, Connecticut, United States
- Site 0239 - Florida Cancer Specialists - East, Daytona Beach, Florida, United States
- Site 0173 - Mount Sinai Medical Center, Miami Beach, Florida, United States
- Site 0308 - Advent Health, Orlando, Florida, United States
- Site 0108 - Emory University Hospital, Atlanta, Georgia, United States
- Site 0236 - Memorial Health, Savannah, Georgia, United States
- Site 0324 - Illinois Cancer Specialists, Niles, Illinois, United States
- Site 0284 - Community Cancer Center North, Indianapolis, Indiana, United States
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05128825 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT07544030A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancertongweihua